Liquidia (NASDAQ:LQDA) Shares Down 6.6% on Disappointing Earnings

Liquidia Corporation (NASDAQ:LQDA) fell 6.6% on Thursday following a dissappointing earnings announcement. The company traded as low as $73.83 and last traded at $73.6150. 2,173,490 shares changed hands during mid-day trading, an increase of 22% from the average session volume of 1,784,219 shares. The stock had previously closed at $78.79.

The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA continues to scale rapidly. Second-quarter net product sales reached approximately $170.4 million, up 31% sequentially. Liquidia reported roughly 5,900 prescriptions and more than 5,000 patients treated since the product’s June 2025 launch. Liquidia Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue, earnings quality and cash flow were strong. Total revenue rose to $171.7 million, ahead of the $168.5 million consensus estimate. Net income was $74.7 million, adjusted EBITDA was $96.3 million, and cash increased to $284.2 million at quarter-end. The results marked Liquidia’s fourth consecutive quarter of improving profitability. Liquidia Corporation Q2 Earnings and Revenues
• Positive Sentiment: Management reiterated an ambitious growth outlook. Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share. The company is also advancing 10 clinical studies involving YUTREPIA and L606, potentially expanding its inhaled-treprostinil opportunity. LQDA Q2 Earnings Call Highlights
• Positive Sentiment: Analysts raised their valuation targets. Needham increased its target to $110 and BTIG to $111, both retaining buy ratings. Bank of America raised its target to $92 but maintained a neutral rating, while Lifesci Capital reaffirmed market perform with a $90 target.
• Neutral Sentiment: The earnings picture was mixed. Diluted EPS of $0.74 was below the $0.76 consensus estimate cited by several outlets, although it exceeded the $0.70 Zacks estimate and improved sharply from a $0.49 loss a year earlier. The slight miss likely prompted some investors to lock in gains after LQDA’s substantial run-up.
• Negative Sentiment: Valuation and insider selling remain risks. Liquidia trades at a very high earnings multiple, while reported insider activity shows 116 sales versus one purchase during the past six months. Management also expects higher second-half research and development spending for the L606 Phase 3 program, which could pressure near-term margins.

Wall Street Analyst Weigh In

LQDA has been the topic of several recent research reports. Oppenheimer set a $75.00 price target on shares of Liquidia in a report on Friday, June 5th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Lifesci Capital reaffirmed a “market perform” rating and issued a $90.00 target price on shares of Liquidia in a research note on Wednesday. Needham & Company LLC increased their target price on Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $106.00 price target on shares of Liquidia in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.08.

Insider Buying and Selling

In other Liquidia news, Director Paul B. Manning sold 200,000 shares of Liquidia stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the transaction, the director owned 716,311 shares in the company, valued at $45,779,436.01. This trade represents a 21.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Stephen M. Bloch sold 242,269 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the transaction, the director owned 1,176,184 shares in the company, valued at $82,838,639.12. The trade was a 17.08% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 1,781,861 shares of company stock worth $124,407,112. 25.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Liquidia

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia in the fourth quarter valued at $25,000. Covestor Ltd raised its holdings in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the period. NewEdge Advisors LLC purchased a new stake in Liquidia during the second quarter valued at about $25,000. Globeflex Capital L P purchased a new stake in Liquidia during the second quarter valued at about $175,000. Finally, Fluent Financial LLC acquired a new position in shares of Liquidia in the second quarter worth about $287,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Performance

The firm’s 50-day moving average price is $78.22 and its two-hundred day moving average price is $54.77. The firm has a market capitalization of $6.46 billion, a PE ratio of 522.47 and a beta of 0.58. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).